The CBD Aging Review Identified No Direct Older-Adult Comparison of Delivery Routes

forensic toxicology working group members October 31, 2026 Forensic Toxicology

The supplied cognitive-aging review discusses potential advantages of alternative CBD delivery routes but reports no direct comparison of multiple routes in older adults. A pharmacokinetic rationale therefore did not establish a clinically superior route.

The proposal concerned absorption and metabolism

The review notes variable oral bioavailability and first-pass metabolism, then considers inhaled, transmucosal, oromucosal and nasal approaches. These routes can change the rate and extent of systemic exposure. They also differ in formulation and administration demands, so they should not be grouped as if every non-oral product produces one consistent exposure.

Higher exposure is not automatically a better cognitive outcome

The review’s suggestion that another route could improve absorption does not demonstrate better memory or fewer adverse effects in older adults. Its authors explicitly identify the absence of a direct multi-route comparison in that population. Their discussion of potentially reduced interaction risk is likewise a research hypothesis, not proof that bypassing first-pass metabolism eliminates CBD’s effects on other medicines.

What a useful comparison would establish

A route comparison would need to measure exposure, cognition, tolerability and relevant concurrent medications under defined conditions. Without that comparison, the review cannot rank delivery methods for an individual patient. Its contribution is to identify which pharmacokinetic and clinical questions should be tested together. Describing those possibilities as already established advantages would move beyond the evidence supplied by the review.

Related analysis: the broader evidence and its limitations.